correl data phase interim pt
today announc posit interim phase data
novel particip across three dose
 seroconvert day singl dose particip across
 dose cohort level bind antibodi greatli
exceed level seen convalesc sera blood sampl
recov gener safe well-toler
transient plan initi phase soon juli
base strong immunogen data toler safeti profil
demonstr increas probabl success
model updat pt stay bullish
interim data show neutral antibodi titer level
 cohort first four patient avail consist level
protect viral replic lung mous challeng model
confer moreov neutral antibodi titer level level seen
convalesc sera significantli level
base strong interim phase well safeti profil
consist seen infecti diseas vaccin studi
phase studi fda clear initi soon phase
studi expect start juli consequ updat po
advanc
manufactur scale match unpreced pace
develop boundari capac continu expand
expect one million dose avail million
doses/month soon ten million doses/month effort
underscor colllabor lonza deliv capac billion
feel comfort speed move sequenc
viru januari interim may asset forward vs peer
higher potenti first-to-market believ leverag
platform accumul safeti databas vaccin candid
facilit clinic develop asset platform especi
updat pt continu see fast-ris opportun
leap closer toward potenti commerci
opportun follow assum weightier share valuat
go forward remind investor potenti mrna platform
potenti bring forward new class medicin stay bullish name
year price histori
found pioneer
new class medicin made
technolog platform transform
bodi cell drug-subst
technolog solut rapid
scale mrna approach
perhap unmatch histori drug
analyst certif import disclosur see disclosur
estim peak revenu potenti initi develop
program rang
estim need rais excess approxim
billion reach commerci
assum first product on-market earlier approv
upsid model
given product develop clinic typic
biotech approv probabl early-stag suggest
achiev minimum product approv current
approv would constitut upsid model
price conserv end biolog
focu reduc biolog develop risk
would constitut signific upsid model
compani stage develop
pre-approv valuat focus potenti futur
revenu stream po platform-multipl approach
base expect launch first
product next year estim total revenu
could reach billion time-frame frame
refer antibodi pioneer genentech herceptin/rituxan/
avastin current constitut total ww
first interim analysi phase dose-
confirm studi cmv
phase initi phase initi juli
phase studi protocol phase
cmv initi
acknowledg possibl signific downsid
estim due inher risk drug develop
worst case stock could littl valu
calcul diseas portfolio-specif revenu potenti assess sum-of-the-part risk-adjust valuat compani
ascrib revenu multipl base develop program potenti expand platform area discount
wacc includ cash billion arriv equiti valu billion per share
believ success next sever year highli depend posit clinic data fda approv launch
current experiment clinic compound biggest risk product candid failur gain fda approv therefor
becom commerci product gain approv risk remain includ manufactur secur favor reimburs
price patient behavior physician adopt product patent protect structur chang healthcar market
exhibit phase interim preclin result
statement million except per product revenu relat good expens paid repurchas redeem redeem convert prefer unit redempt stock incom avail common per pro forma share per share dilut pro forma share dilut share outperform
modalityprogramprogram indicationtimingmilestoneprophylact syncyti viru rsv rsv phase safeti immunogen data syncyti viru rsv vaccinewil move plan phase studi time due lower potenc base preclin cmv interim analysi phase dose-confirm studi cmv phase plan cmv metapneumoviru parainfluenza viru enrol paus due seroposit age de-escal immunogen data vaccineadvanc subject vaccineadvanc subject develop plan follow posit phase interim viru ebv rsv file phase data phase initi soon phase initi vaccineadvanc subject fundingcanc cancer vaccin clinic data led cancer vaccin on-going phase kra cancer vaccin merck studyintratumor solid tumors/lymphoma advanc ovarian carcinoma ph dose phase advanc ovarian carcinoma triplet solid dose escal initi dose disease-specif solid phase studi mrna encod inject intratumorallyloc regen myocardi cardiac function data random phase studysystem secret chikungunya enrol paus due data addit cohort heart file fabri fabri ind filingsystem intracellular methylmalon acidemia enrol paus due proof concept biomark phase propion acidemia enrol paus due pa enrol pa phase i/ii phenylketonuria pku ind glycogen storag disord type ind file outperform
stock price compani mention report
